Filing Flows › Progyny (PGNY) › Guidance & outlook
Progyny (PGNY) guidance and outlook
Progyny (PGNY) raised its guidance on Nov 4, 2026: Net income $107M–$111M for FY2026; EBITDA $235M–$240M for FY2026; EPS $1.00 for FY2026; Revenue $345M–$365M for Q4 2026. Progyny's 10-Q filed Nov 5, 2026 makes 17 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Net income | FY2026 | $107M–$111M | raised |
| EBITDA | FY2026 | $235M–$240M | raised |
| EPS | FY2026 | $1.00 | reaffirmed |
| Revenue | Q4 2026 | $345M–$365M | new |
| Revenue | Q4 2026 | +8.3% to +14.6% | new |
| Net income | Q4 2026 | $28.5M–$32.1M | new |
| EBITDA | Q4 2026 | $57.9M–$62.9M | new |
| EPS | Q4 2026 | $1.00 | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- This allows us to provide members with access to our PCAs for fertility and family building education and guidance and other digital tools to all of our members, regardless of whether they ultimately pursue fertility treatment.
- In addition to the measures presented in our consolidated financial statements, we use the following key operational and business metrics to evaluate our business, measure our performance, develop financial forecasts, and make strategic decisions.
- We intend to continue to drive new client acquisition by investing significantly in sales and marketing to engage, educate and drive awareness of the unmet need around fertility solutions among benefits executives.
- We are expanding our client base within each industry and have an industry-specific strategy that enables us to most effectively target our addressable market.
- Revenue is also accrued for authorized Smart Cycle services rendered based on member appointments scheduled with a fertility specialist in our network but for which no claim has yet been reported, net of expected changes and cancellations of services.
- Clients who purchase our fertility benefits solution also pay us a population based PEPM fee which provides access to our PCAs for fertility and family building education and guidance and other digital tools for all of our covered members, regardless of whether or not they ultimately pursue fertility treatment.
- We expect that gross profit and gross margin will continue to be affected by various factors, including the geographic location where treatments are performed, as well as pricing with each of our clients, provider clinics, labs, specialty pharmacies and pharmaceutical companies, all of which are negotiated separately, have different contracting start and end dates and durations, which are not coterminous with…
- Additionally, staffing levels and the related personnel costs, including stock-based compensation expense, and other costs necessary to deliver our care management services will continue to grow as we continue to add clients and their associated members.
- We expect sales and marketing expense to continue to increase in absolute dollars as we continue to invest and grow our business.
- We anticipate that we will incur additional general and administrative expenses on an ongoing basis to support the growth of our business.
- GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook.
- We believe that our existing cash and cash equivalents, including the proceeds from our marketable securities, cash flow from operations, and the availability of funds under the Facility will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months.
Progyny's latest quarter
Progyny, Q3 2026: revenue $341M (+9% year over year), operating margin 10.3%, net earnings $26.3M, operating cash flow $56.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Progyny raise or lower its guidance?
Progyny (PGNY) raised its guidance on Nov 4, 2026: Net income $107M–$111M for FY2026; EBITDA $235M–$240M for FY2026; EPS $1.00 for FY2026; Revenue $345M–$365M for Q4 2026.
What does Progyny expect?
This allows us to provide members with access to our PCAs for fertility and family building education and guidance and other digital tools to all of our members, regardless of whether they ultimately pursue fertility treatment. In addition to the measures presented in our consolidated financial statements, we use the following key operational and business metrics to evaluate our business, measure our performance, develop financial forecasts, and make strategic decisions. We intend to continue to drive new client acquisition by investing significantly in sales and marketing to engage, educate a
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.